SCHEMBL6410865

SCHEMBL6410865

O=C1CN(Cc2ccccc2)CCC1C(c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.66

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 9/20 0.66
SLC6A3 Q01959 2/20 0.51
SLC6A4 P31645 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6410544 0.91 TACR1 (0.62) TACR1
Hydrochloric Acid SCHEMBL6407071 0.89 TACR1 (0.63) TACR1
SCHEMBL6406538 0.88 TACR1 (0.79) TACR1
SCHEMBL6405969 0.82 TACR1 (0.52) TACR1
SCHEMBL10460713 0.80 SLC6A3 (0.60) TACR1SLC6A3SLC6A4
SCHEMBL6405523 0.80 TACR1 (1.00) TACR1
SCHEMBL6406374 0.78 TACR1 (0.76) TACR1
SCHEMBL4635606 0.78 BCHE (0.52) TACR1
SCHEMBL6449236 0.76 TACR1 (0.61) TACR1
SCHEMBL6414907 0.75 TACR1 (0.46) TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038072-A1 Nitrogeneous cyclic ketone derivative, process for producing the same, and use TAKEDA CHEMICAL INDUSTRIES, LTD. 2005-02-17 US disclosed
EP-1460062-A1 NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038072-A1 Nitrogeneous cyclic ketone derivative, process for producing the same, and use BDKRB1, BDKRB2, TACR1 TACR1 3/4885SLC6A3 1499/4885SLC6A4 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.